Immunotherapy in GU Cancers

After 3 years of follow-up in the ZUMA-5 trial, patients with relapsed/refractory indolent non-Hodgkin lymphoma treated with axicabtagene ciloleucel had durable responses.

In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the newest biomarkers for metastatic prostate cancer, how they inform oncologists' decisions, and challenges to overcome with targeted therapy.

Courtney D. DiNardo, MD, MSCE, provided an overview of venetoclax resistance and interrelated mechanisms, with a spotlight on kinase signaling pathways, TP53 mutation, monocytic, and other forms of resistance.

In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD and Nicholas J. Vogelzang, MD, discuss he optimal sequencing of therapies for a specific patient with metastatic castration-resistant prostate cancer.

Late-stage clinical trials are evaluating MDM2 inhibitors that target p53 in both solid tumors and hematologic malignancies.